Supriya Lifescience Q1FY27: PAT down 31% YoY on margin squeeze despite 31% revenue growth

Supriya Lifescience's standalone Q1 FY27 (quarter ended June 30, 2026) revenue rose 30.8% YoY to ₹189.7 Cr (from ₹145.1 Cr), but standalone PAT fell 30.9% YoY to ₹24.0 Cr (from ₹34.8 Cr) — a classic case of top-line growth masking a sharp margin squeeze. Sequentially the picture is starker: revenue was down 31.4% and PAT down 67.6% versus the seasonally strong Q4 FY26 (₹276.5 Cr revenue, ₹74.2 Cr PAT), though Q4-to-Q1 sequential drops are typical for this business given its export-driven, lumpy order pattern. EPS came in at ₹2.99 versus ₹9.22 in Q4 FY26 and ₹4.32 a year ago. The compression sits squarely on the cost line. Cost of materials consumed jumped to 57.7% of revenue (from ~30% both YoY and QoQ), and even after netting off a large finished-goods inventory build, net material cost intensity still rose to 29.7% of sales from 21.9% a year ago. Other expenditure also crept up to 30.3% of revenue from 26.8% YoY. Total expenses absorbed 79.9% of revenue versus 69.2% a year ago, pulling operating margin (PBT + depreciation + finance cost, over revenue) down to 25.0% from 35.6% YoY and 35.3% QoQ — well below management's own FY27 guidance band of 33-35% EBITDA margin. Net profit margin fell to 12.7% from 23.6% YoY and 26.5% QoQ. On guidance, management had targeted ~20% annual FY27 revenue growth toward a ₹1,000 Cr full-year target with 33-35% EBITDA margins; this quarter's 30.8% YoY revenue growth runs ahead of that pace, but the margin miss means the quarter reads as missing the guided profitability band even as topline outpaces it. Against Street, a pre-result trailing-growth model (Univest) had pencilled in a YoY decline — revenue ~₹131 Cr and PAT ~₹27 Cr — so the actual revenue print is a sizeable beat, but PAT of ₹24.0 Cr still came in below that ₹27 Cr estimate, a modest miss on the bottom line. No management press release was available to cross-check the company's own framing of the quarter. Separately, note 3 to the results discloses that export goods were intercepted and held in Customs custody as of quarter-end yet already recognised as a sale since the shipment had reached Customs for export processing — a disclosure that lines up with the company's July 2026 announcement that a General Manager was arrested by Customs and remains in judicial custody, a live overhang investors should track alongside the margin trajectory.